GSK's Total Assets for the quarter that ended in Mar. 2026 was MXN1,511,597 Mil.
During the past 12 months, GSK's average Total Assets Growth Rate was 5.70% per year.
During the past 3 years, the average Total Assets Growth Rate was 3.40% per year.
During the past 5 years, the average Total Assets Growth Rate was -5.80% per year.
During the past 10 years, the average Total Assets Growth Rate was 1.00% per year.
During the past 13 years, GSK's highest 3-Year average Total Assets Growth Rate was 38.50%. The lowest was -11.30%. And the median was 11.50%.
Total Assets is connected with ROA %. GSK's annualizedROA % for the quarter that ended in Mar. 2026 was 11.19%. Total Assets is also linked to Revenue through Asset Turnover. GSK's Asset Turnover for the quarter that ended in Mar. 2026 was 0.12.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
GSK's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
GSK Total Assets Related Terms
GSK Total Assets Historical Data
* Premium members only.
The historical data trend for GSK's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
GSK's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Assets of MXN1,511,597 Mil mean?
GSK (MEX:GSKN) has a Total Assets of MXN1,511,597 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on GSK and its competitors.
Is GSK's Total Assets too high?
GSK's current Total Assets is MXN1,511,597 Mil. Overall, GSK has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GSK's Total Assets compare to LLY and JNJ?
GSK's Total Assets of MXN1,511,597 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on GSK and its competitors. GSK's current Total Assets is MXN1,511,597 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (MEX:GSKN) is currently considered Fairly Valued. The stock's GF Value™ is MXN818.82, compared to a current price of MXN901.11 — trading 10% above its estimated fair value. The current Total Assets is MXN1,511,597 Mil. GSK's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For GSK (MEX:GSKN), the current Total Assets is MXN1,511,597 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (MEX:GSKN) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of MXN901.11 is trading 10% above its estimated GF Value™ of MXN818.82.
GuruFocus considers GSK to be Fairly Valued.
Key valuation signals for MEX:GSKN:
Total Assets: MXN1,511,597 Mil
GF Value™: MXN818.82 vs. price of MXN901.11 (10% above fair value)
No single metric tells the full story. See the MEX:GSKN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
73GF Score
Get the complete analysis for MEX:GSKN
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GSKN has been successfully added to your 
